Heart failure research in the Netherlands has contributed to significant advancements in pharmacotherapy, biomarker-guided therapy, and personalized medicine for patients with heart failure.
This review provides an overview of heart failure research and clinical trials conducted in the Netherlands.
Heart failure (HF) remains a major global problem. In the Netherlands, 1.5-2.0% of the total population is diagnosed with HF. Over 30,000 HF patients are admitted annually in the Netherlands, and this number is expected to further increase given the ageing population and the chronic nature of HF. Despite ongoing efforts to reduce the burden of HF, morbidity and mortality rates of this disease remain high. However, several new treatment modalities have become available or are expected to become available in the coming years. This review will provide an overview of HF research conducted in the Netherlands (often in an international setting) that may have clinical consequences for diagnosis, treatment and prevention of HF, and will also evaluate outcomes of larger clinical trials that have been conducted in the Netherlands.
Meems et al. (Sat,) conducted a review in Heart failure. Heart failure management was evaluated. Heart failure research in the Netherlands has contributed to significant advancements in pharmacotherapy, biomarker-guided therapy, and personalized medicine for patients with heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: